Semaglutide After Heart Ablation Cuts Atrial Fibrillation Recurrence Nearly in Half | Research

The takeaway

Obese patients who took semaglutide around the time of catheter ablation for atrial fibrillation had 48% lower recurrence risk and lost an average of 11.8 kg over 18 months.

48% lower recurrence
Semaglutide as adjunct to catheter ablation in obese AF patients over 18 months

What the researchers found

Semaglutide as adjunct to AF catheter ablation reduced arrhythmia recurrence (HR 0.52, 95% CI 0.34–0.78) with freedom from recurrence of 80.2% vs. 65.2% at 18 months.

Why it matters

Obesity is a major driver of AF recurrence after ablation. This study suggests semaglutide could transform post-ablation care by addressing the underlying metabolic driver, not just the electrical problem.

How the study worked

Single-center propensity-matched study with 362 obese patients (181 per group) undergoing first-time catheter ablation, monitored by implantable cardiac monitors.

What this study cannot tell us

Single-center, non-randomized study; propensity matching cannot eliminate all confounders. Continuous monitoring via implantable devices is a strength but the study population may not generalize to all AF patients.

How to read the evidence

Propensity-matched cohort with continuous rhythm monitoring—strong observational design but not randomized.

When this study was published

Published in 2026 with data from 2019–2024.

The bigger picture

This adds to growing evidence that GLP-1 drugs have cardiovascular benefits beyond diabetes, potentially becoming standard adjunctive therapy for obesity-related cardiac conditions.

Questions still open

Would a randomized controlled trial confirm these impressive results?
Does the benefit extend to persistent AF or only paroxysmal AF?
Is the benefit primarily from weight loss, or do GLP-1 drugs have direct anti-arrhythmic properties?

Common questions

Can semaglutide prevent atrial fibrillation from coming back after ablation?

This study found that obese patients who took semaglutide around the time of their AF ablation had about half the recurrence risk compared to matched controls, likely driven by significant weight loss and reduced metabolic inflammation.

Do I need to be obese for semaglutide to help with AF?

This study specifically enrolled obese patients (BMI ≥30). Whether the AF benefit extends to non-obese patients is unknown and would need separate study.

Read the original research

Semaglutide as adjunctive therapy to catheter ablation in obesity-related paroxysmal atrial fibrillation.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 28(2)

View on PubMed ↗Publisher’s paper ↗

Citation

Ciconte, Giuseppe; Salerno, Raffaele; Fuga, Alessandro; Vuturo, Alessia; Boccellino, Antonio; Negro, Gabriele; Rondine, Roberto; Ballarotto, Marco; Ciaccio, Cristiano; Izzo, Antonio; Morciano, Davide Antonio; Garbelli, Arianna; Giannelli, Luigi; Maiolo, Vincenzo; Calovic, Zarko; Anastasia, Luigi; Pappone, Carlo. (2026). Semaglutide as adjunctive therapy to catheter ablation in obesity-related paroxysmal atrial fibrillation.. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 28(2). https://doi.org/10.1093/europace/euag018